Actinic Keratosis Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Actinic Keratosis Treatment Market Analysis
The actinic keratosis treatment market is expected to register a CAGR of 5.3% during the forecast period.
The COVID-19 pandemic had a significant impact on the actinic keratosis treatment market. There was a decrease in the number of aesthetic procedures performed worldwide during the COVID-19 pandemic to reduce the risk of viral transmission. For instance, according to an article published by Elsevier Public Health Emergency Collection, in February 2021, during the crisis, dermatologists were involved in managing cutaneous manifestations related to COVID-19 and occupational disease caused by personal protective equipment. The reduction in the number of procedures was attributed to the fear and risk of infection from COVID-19. However, with the adoption of telemedicine and teleconsultations during the pandemic, the demand for dermatological treatment increased, which led to a rise in the demand for actinic keratosis treatment. However, as COVID-19 cases have declined and the pandemic accelerated the use of teledermatology, the studied market is expected to project stable growth over the studied period.
The increasing prevalence of actinic keratosis, growing demand for minimally invasive procedures, and increasing research and development for developing novel therapies are the key driving factors in the market. For instance, according to an article published by the Indian Journal of Dermatology, in April 2022, actinic keratosis is one of the most frequently seen signs in the outpatient setting and was diagnosed at more than 10% of dermatology visits. In the UK, 15%-23% of individuals have actinic keratosis lesions, and this reaches 37.5% among people older than 50 years of age. This is likely to increase the adoption of the available treatment and early diagnosis of the disease. Furthermore, according to an article published by MDPI, in June 2022, photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) is an emerging treatment option in the care of actinic keratosis. This increase in the prevalence of actinic keratosis leading to a surge in minimally invasive procedures such as photodynamic therapy is expected to aid the overall market growth in the studied period.
The recent product launches by the key market players are also aiding the market growth. For instance, in November 2022, Biofrontera Inc. launched a randomized, double-blind, vehicle-controlled, multicenter Phase 3 clinical study to evaluate the safety and efficacy of Ameluz and BF-RhodoLED XL in the field-directed treatment of actinic keratosis (AK) on the extremities, neck, and trunk. Furthermore, in September 2021, Almirall, S.A. launched Klisyri (tirbanibulin) in Germany and the U.K. The product was launched upon approval from the U.K.'s Medicines & Healthcare Products Regulatory Agency (MHRA) and the European Commission for treating actinic keratosis of the scalp and face in adults.
Risk factors associated with available treatment options may restrain the market growth over the forecast period.
Actinic Keratosis Treatment Market Trends
This section covers the major market trends shaping the Actinic Keratosis Treatment Market according to our research experts:
Photodynamic Therapy Segment is Expected to Hold a Significant Market Share in the Actinic Keratosis Treatment Market
The photodynamic therapy segment holds a significant share of the actinic keratosis treatment market. It is anticipated to show a similar trend over the forecast period due to the noninvasive nature of the treatment, high target specificity, and a lower risk of scarring. The rising incidence of baldness, skin wrinkling, and sunburn patches have led to increased actinic keratosis cases. According to an article published by the National Library of Medicine in May 2022, countries closer to the equator demonstrate higher rates of actinic keratosis. The prevalence rates of actinic keratosis in Australia are close to 60% due to its proximity to the equator.
The recent initiatives, launches, and agreements by the market players are also aiding the market growth. For instance, in December 2022, Biofrontera AG's Scandinavian licensing partner Galenica AB, Malmö, Sweden, started the commercialization of Ameluz and BF-RhodoLED in Finland after Galenica had already successfully launched the Ameluz-photodynamic therapy in Sweden, Norway, and Denmark in mid-2021 under a licensing agreement at the end of 2020. Also, in December 2021, Biofrontera Inc. enrolled in a Phase 1 study to evaluate the safety and tolerability of photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) using three tubes of Ameluz together with the company's BF-RhodoLED XL lamp. Such product approvals are expected to drive the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period
North America is expected to hold a significant share of the global actinic keratosis treatment market due to the growing prevalence of actinic keratosis coupled with a higher proportion of older individuals in this region. For instance, as per the 2021 America's Health Rankings data, over 54 million people over the age of 65 are living in the United States, comprising 16.5% of the total population. It was projected that the nation's total number of adults aged 65 and older will rise to an estimated 85.7 million by the year 2050. Furthermore, according to a Statistics Canada update, in April 2022, 1 in 5 Canadians (19%) were aged 65 and older (7 million), and approximately 25% were baby boomers (9.2 million) in 2021. Additionally, according to a World Bank update in January 2023, the population ages 65 and above in Mexico was reported at 8.13% in 2021.
The recent initiatives, launches, and agreements by the market players are also aiding the market growth. For instance, in February 2021, Almirall launched its novel microtubule inhibitor, tirbanibulin (Klisyri, Almirall), for the topical treatment of actinic keratosis (AK) on the face and scalp in the United States. Such development is expected to drive the growth of the market.
Actinic Keratosis Treatment Industry Overview
The actinic keratosis treatment market is moderately concentrated in nature due to the presence of companies operating globally as well as regionally, including Bausch Health Companies Inc, LEO Pharma A/S, Almirall, S.A., GlaxoSmithKline plc, Cipher Pharmaceuticals Inc., Biofrontera AG, Sun Pharmaceutical Industries Limited, 3M Company, Galderma SA, Alma Lasers, and Novartis AG and Hill Dermaceuticals, Inc.
Actinic Keratosis Treatment Market Leaders
-
Sun Pharmaceutical Industries Limited
-
Biofrontera AG
-
Bausch Health Companies Inc.
-
LEO Pharma A/S
-
Almirall, S.A.
*Disclaimer: Major Players sorted in no particular order
Actinic Keratosis Treatment Market News
- In September 2022, PharmaEssentia Corporation received approval from Taiwan's Ministry of Health and Welfare (MOHW) for KX01 as the New Drug Application for Actinic Keratosis with the license number Wei-Bu-Yao-Shu-Zi No. 028364.
- In May 2022, Actinic Keratosis Global Day was launched by Almirall in partnership with Euromelanoma and AEDV Fundación Piel Sana and coincided with Skin Cancer Awareness Month.
Actinic Keratosis Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Actinic Keratosis Worldwide
4.2.2 Growing Demand for Minimally Invasive Procedures
4.2.3 Favorable Reimbursement Policies
4.3 Market Restraints
4.3.1 Risk Factors Associated With Available Treatment Options
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapy
5.1.1 Topical Medications
5.1.1.1 Fluorouracil
5.1.1.2 Imiquimod
5.1.1.3 Ingenol Mebutate
5.1.1.4 Other Medications
5.1.2 Procedures
5.1.2.1 Photodynamic Therapy
5.1.2.2 Laser
5.1.2.3 Other Procedures
5.2 By End User
5.2.1 Hospitals and Oncology Centers
5.2.2 Dermatology Clinics
5.2.3 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bausch Health Companies Inc
6.1.2 Almirall, S.A.
6.1.3 Biofrontera AG
6.1.4 Sun Pharmaceutical Industries Limited
6.1.5 Galderma SA
6.1.6 Alma Lasers
6.1.7 Hill Dermaceuticals, Inc
6.1.8 GlaxoSmithKline plc
6.1.9 Cipher Pharmaceuticals Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Actinic Keratosis Treatment Industry Segmentation
As per the scope of the report, actinic keratosis is a rough, scaly patch on skin that develops from years of exposure to solar radiation. It is commonly found on the face, lips, ears, back of hands, forearms, scalp, or neck.
The Actinic Keratosis Treatment Market is Segmented By Therapy Type (Topical Medications (Fluorouracil, Imiquimod, Ingenol Mebutate, and Other Medications), and Procedures (Photodynamic Therapy, Laser, and Other Procedures)), End User (Hospitals and Oncology Centers, Dermatology Clinics, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market size and forecasts in value (USD million) for the above segments.
| By Therapy | ||||||
| ||||||
|
| By End User | |
| Hospitals and Oncology Centers | |
| Dermatology Clinics | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Actinic Keratosis Treatment Market Research FAQs
What is the current Global Actinic Keratosis Treatment Market size?
The Global Actinic Keratosis Treatment Market is projected to register a CAGR of 5.30% during the forecast period (2024-2029)
Who are the key players in Global Actinic Keratosis Treatment Market?
Sun Pharmaceutical Industries Limited, Biofrontera AG, Bausch Health Companies Inc., LEO Pharma A/S and Almirall, S.A. are the major companies operating in the Global Actinic Keratosis Treatment Market.
Which is the fastest growing region in Global Actinic Keratosis Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Actinic Keratosis Treatment Market?
In 2024, the North America accounts for the largest market share in Global Actinic Keratosis Treatment Market.
What years does this Global Actinic Keratosis Treatment Market cover?
The report covers the Global Actinic Keratosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Actinic Keratosis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Actinic Keratosis Treatment Industry Report
Statistics for the 2024 Global Actinic Keratosis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Actinic Keratosis Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
